Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab in advanced NET/GEP-NEC
NCT02955069Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2017
- Primary completion
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of spartalizumab in Neuroendocrine Neoplasm (NEN) and gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), sponsored by Novartis. Primary endpoint: Overall Response Rate at 1.5 years. Started Feb 2017; status: completed.
02
Drugs
spartalizumab
03
Conditions
Neuroendocrine Neoplasm (NEN)gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on NCT02955069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955069.